Tumor cells cotransduced with B7.1 and γ-IFN induce effective rejection of established parental tumor

Gene Therapy

Volumn 6, Issue 2, 1999, Pages 253-262

  Yang, S ^a   Vervaert, C E ^a   Seigler, H F ^a   Darrow, T L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

IFN; B7.1; Costimulation; CTL; Gene therapy; Immunotherapy; Tumor immunity

Indexed keywords

CYTOKINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR VACCINE;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FIBROSARCOMA; GENE THERAPY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; IMMUNOGENICITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD80; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; MICE; MICE, INBRED STRAINS; NEOPLASMS; RETROVIRIDAE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032990464     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300820     Document Type: Article

References (46)

1. Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7: 445-480.
2. Linsley PS, Ledberter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212.
3. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349-1356.
4. Sharpe AH. Analysis of lymphocyte costimulation in vivo using transgenic and 'knockout' mice. Curr Opin Immunol 1995; 7: 389-395.
5. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065-1068.
6. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14: 483-486.
7. Chen L et al. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
8. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
9. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J Exp Med 1994; 179: 1205-1214.
10. Baskar S et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules. Proc Natl Acad Sci USA 1993; 90: 5687-5690.
11. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 1994; 153: 421-428.
12. Chen L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-532.
13. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995; 154: 2794-2800.
14. Mukherji D, Chakraborty NG. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol. 1995; 7: 175-184.
15. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today 1997; 18: 292-299.
16. Gattido F, Ruiz-Cabello F. MHC expression of human tumors: its relevance for local tumor growth and metastasis. Semin Cancer Biol 1991; 2: 3-10.
17. Ruiter D, Mattijssen V, Brooecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2: 35-45.
18. Ostrand-Rosenberg S, Cole GA, Nishimura MI, Clements VK. Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host. Cell Immunol 1990; 128: 152-164.
19. Mandelboim O, Feldman M, Eisenbach L. H-2K double transfectants of tumor cells as antimetastatic cellular vaccines in heterozygous recipients. Implications for the T cell repertoire. J Immunol 1992; 148: 3666-3673.
20. Xu F, Carlos T, Khokha R, Gorelik E. Reduction of metastatic and adhesion properties and up-regulation of TIMP-1 in BL6 melanoma cells transfected with MHC class 1 genes. Proc Am Assoc Cancer Res 1997; 38: 166 (Abstr. 141).
21. Ostrand-Rosenberg S, Clements VK, Armstrong T, Pulaski B. Immunotherapy with class II-transfected tumor cells. Proc Am Assoc Cancer Res. 1997; 38: 346 (Abstr. 2318).
22. k by gene transfer into Sal sarcoma cells using a non-cytolytic recombinant vaccinia virus. Proc Am Assoc Cancer Res 1997; 38: 12 (Abstr. 79).
23. Dar MM et al. Immunological memory induced by genetically transduced tumor cells. Ann Surg Oncol 1996; 3: 247-254.
24. Raes G et al. Immunogenization of a murine T-cell lymphoma via transfection with interferon-gamma. Leukemia 1995; 9 (Suppl. 1): S121-S127.
25. Lurquin C et al. Structure of the gene of tum-transplantation antigen p91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 1989; 58: 293-303.
26. Hellstrom KE, Hellstrom I. Principles of tumor immunity: tumor antigens. In: De Vita VT Jr, Hellman S, Rosenberg SA (eds). Biologic Therapy of Cancer. JB Lippincott Co: Philadelphia, 1991, p 35.
27. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1-4.
28. Boon T et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994; 12: 337-365.
29. Shu S, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985; 45: 1657-1662.
30. Liu Y, Janeway C. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA. 1992; 89: 3845-3849.
31. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 1995; 181: 619-629.
32. Schoenberger S et al. Efficient direct priming of tumor-specific cytotoxic T lymphocytes in vivo by an engineered APC. Cancer Res 1998; 58: 3094-3100.
33. + cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993; 177: 1791-1796.
34. Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol 1994; 152: 3361-3369.
35. Chen PW, Ananthaswamy HM. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J Immunol 1993; 151: 244-255.
36. Yang S, Darrow TL, Seigler HF. Generation of primary tumor specific CTL from autologous and HLA class I-matched allogeneic PBLs by B7 gene modified melanoma cells. Cancer Res 1997; 57: 1561-1568.
37. Iezzi G, Protti MP, Rugarli C, Bellone M. B7.1 expression on tumor cells circumvents the need of professional antigen presentation for in vitro propagation of cytotoxic T cell lines. Cancer Res 1996; 56: 11-15.
38. Fenton R, Turcovski-Corrales SM, Taub DD. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell J lines. J Immunother 1998; 21: 95-108.
39. Cayeux S et al. Influence of gene-modified (IL-1, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J Immunol 1997; 158: 2834-2841.
40. + T lymphocytes. J Immunol 1998; 160: 661-666.
41. Maric M et al. Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role of costimulation by B7 on both tumor and host antigen-presenting cells. Cancer Res 1998; 58: 3376-3384.
42. Huang AYC et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
43. Freeman GJ et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human b lymphocyte activation antigen B7. J Exp Med 1991; 174: 625-631.
44. Lewis JA. Biological assays for interferons. In: Clemens MJ, Morris AG, Gearing AJH (eds). Lymphokines and Interferons: A Practical Approach. IRL Press: Washington DC, 1987, p 73.
45. Widmer MB, Voice RF, Conlon PJ, Grabstein KH. Precursor frequency and lytic specificity of interleukin 2 and interleukin 4-responsive murine lymphocytes. Transplantation 1990; 49: 743-748.
46. Taswell, C. Limiting dilution assays for the determination of immunocompetent cell frequencies. J Immunol 1981; 126: 1614-1619.